Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Inotuzumab ozogamicin by Pfizer for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Inotuzumab ozogamicin is under clinical development by Pfizer and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
Data Insights
Inotuzumab ozogamicin by Pfizer for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval
Inotuzumab ozogamicin is under clinical development by Pfizer and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid...